|Bid||293.68 x 800|
|Ask||293.98 x 1200|
|Day's Range||292.52 - 297.43|
|52 Week Range||220.05 - 345.15|
|Beta (3Y Monthly)||1.55|
|PE Ratio (TTM)||24.31|
|Earnings Date||May 6, 2019 - May 10, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||357.50|
"Market conditions are changing. The continued rise in interest rates suggests we are in the early stages of a bond bear market, which could intensify as central banks withdraw liquidity. The receding tide of liquidity will start to reveal more rocks beyond what has been exposed in emerging markets so far, and the value of […]
Bio-Rad Laboratories, Inc. (NYSE:BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the first quarter 2019 on Wednesday, May 8, 2019, following the close of the market. Bio-Rad Laboratories, Inc. (NYSE:BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets.
A small handful of the Bay Area's largest tech employers, including Facebook, Palo Alto Networks, Splunk and Broadcom, pay their median employee above $200,000 per year.
Bio Rad Laboratories Inc NYSE:BIOView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is extremely low for BIO with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting BIO. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding BIO are favorable with net inflows of $183.01 billion. This was the highest net inflow seen over the last one-year.Error parsing the SmartText Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
The regulatory go-ahead is in line with Bio-Rad's (BIO) strategy of strengthening in the transfusion medicine market of the United States.
Stock futures: Zogenix plunged early Tuesday on FDA news, while GW Pharma stock rose and PhaseBio stock soared. Bio-Rad won an FDA approval, but shares were quiet near a buy point.
Bio-Rad Laboratories, Inc. , a global leader of life science research and clinical diagnostic products, today announced that it has received 510 clearance from the U.S.
The recent development will help Bio-Rad (BIO) rake in increased top-line contributions from the Clinical Diagnostics business.
Bio-Rad Laboratories, Inc. (NYSE:BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the appointment of Ilan Daskal as Executive Vice President and Chief Financial Officer, effective April 6, 2019. Mr. Daskal comes to Bio-Rad from Lumileds, where he served as Chief Financial Officer. Mr. Daskal holds a Masters in Finance degree from City University of New York and a BB in Accounting from Tel-Aviv College of Business in Israel.
Tesla last year awarded CEO Elon Musk a stock options package worth $2.28 billion — which works out to some 40,668 times more than what the company’s median worker earns in a year.
Bio-Rad Laboratories, Inc. , a global leader of life science research and clinical diagnostic products, today announced that it has received U.S. Food and Drug Administration clearance for its BioPlex 2200 Lyme Total Assay, an innovative multiplex test method to aid in the diagnosis of Lyme disease.
NEW YORK, March 27, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Bio-Rad Laboratories, Inc. (NYSE:BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that it had received an expected notice from the New York Stock Exchange (the “NYSE”) stating that the Company is not in compliance with the NYSE's continued listing requirements under the timely filing criteria established in Section 802.01E of the NYSE Listed Company Manual due to the Company’s delay in filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2018 (the "2018 Form 10-K"). As previously disclosed, the reason for the delay is the additional time needed by Bio-Rad to complete its year-end procedures, including its assessment of the effectiveness of the Company’s internal control over financial reporting as of December 31, 2018.
Company Alignment on Long-term Strategic Agenda and Investment on Operation and Execution MONTEVIDEO, Uruguay , March 22, 2019 /PRNewswire/ -- Biotoscana Investments S.A. (B3: GBIO33), a biopharmaceutical ...
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Bio-Rad (BIO).